Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.00015, expectations were $-0.16.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Perceptive Advisors Joseph Edelman | 12,594,211 | $37,026,980 | 0.64% | |
2. | Cercano Management Chris Orndorff | 7,172,985 | $21,088,576 | 0.58% | |
3. | Alyeska Investment Group Anand Parekh | 441,018 | $1,296,593 | 0% | |
4. | Clearline Capital Marc Majzner | 168,984 | $496,813 | -28% | 0.02% |
5. | Wexford Capital Charles Davidson | 159,101 | $467,757 | 0.09% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$2.84 | 12,044 | Large Shareholder, Officer, Director | 10,064,488 | 2024-03-11 | Filing | |
$2.99 | 2,430 | Large Shareholder, Officer, Director | 10,052,444 | 2024-03-08 | Filing | |
$2.89 | 18,854 | Large Shareholder, Officer, Director | 10,050,014 | 2024-03-07 | Filing | |
$2.70 | 9,267 | Large Shareholder, Officer, Director | 10,031,160 | 2024-03-06 | Filing | |
$2.65 | 7,405 | Large Shareholder, Officer, Director | 10,021,893 | 2024-03-05 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 17,653,917 | $52,785,212 | 3.54% | |
2. | 3,893,637 | $11,641,976 | 0% | |
3. | 2,829,798 | $8,461,096 | 0% | |
4. | 2,207,619 | $6,600,781 | 0.23% | |
5. | 2,000,000 | $5,980,000 | 0.57% |